CIRM Funded Clinical Trials

A Phase 1b/2a Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in B-Cell Cancers

Disease Area:

B cell cancers, Leukemia

Investigator:

Thomas J Kipps

Institution:

University of California, San Diego

CIRM Grant:

CLIN2-10192 (Closed)

Award Value:

$18,292,674.00

Trial Sponsor:

University of California, San Diego

Trial Stage:

Phase 1/2

Trial Status:

Active, not recruiting

Targeted Enrollment:

102

ClinicalTrials.gov ID:

NCT03088878

Details:

Cancer is a leading cause of death in California. Many cancers resist current therapies due to therapy-resistant cancer stem cells (CSCs). A team at UCSD is testing an antibody therapy called cirmtuzumab in a clinical trial study to treat a blood cancer, Chronic Lymphocytic Leukemia (CLL). The antibody recognizes and attaches to a protein on the surface of cancer stem cells. This attachment disables the protein which slows the growth of the leukemia and makes it more vulnerable to anti-cancer drugs. The team is also testing cirmtuzumab in combination with an approved cancer fighting drug called ibrutinib, to target can- cer stem cells in a separate clinical trial. The aim is that combining cirmtuzumab with ibrutinib will improve cancer remission and long-term cancer control in patients.

Design:

Open label. Phase 1b dose finding, followed by Phase 2a.

Goal:

Evaluate dosing and complete response rate.

News about this clinical trial:

Contact Trial Sponsor